Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Nemus Bioscience, Inc. (OTC: NMUS).

Full DD Report for NMUS

You must become a subscriber to view this report.


Recent News from (OTC: NMUS)

NEMUS Bioscience to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Long Beach, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murp...
Source: GlobeNewswire
Date: August, 28 2018 08:00
UPDATE: Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma
Long Beach, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with  Albany Molecular Resea...
Source: GlobeNewswire
Date: August, 01 2018 09:53
Nemus Bioscience inks deal with Albany Molecular Research to manufacture cannabinoid-based API for glaucoma
Nemus Bioscience ( OTCQB:NMUS ) announces an agreement with Albany Molecular Research (AMRI) for the development and manufacture of Nemus' proprietary cannabinoid-based active pharmaceutical ingredients (API). More news on: Nemus Bioscience, Inc., Healthcare stocks news, Read mo...
Source: SeekingAlpha
Date: August, 01 2018 09:30
Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma
Long Beach, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with Albany Molecular Researc...
Source: GlobeNewswire
Date: August, 01 2018 08:30
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
FRAMINGHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit Dhillon, former Pr...
Source: GlobeNewswire
Date: July, 20 2018 07:30
Nemus Bioscience Discusses Pre-Clinical Developments and Target Indications in New SNNLive Video Interview with StockNewsNow.com
LOS ANGELES, CA / ACCESSWIRE / July 16, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Brian Murphy, MD, MPH, MBA, CEO/CMO of NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based the...
Source: ACCESSWIRE IA
Date: July, 16 2018 08:30
VIDEO: Nemus Bioscience, Inc. (OTCQB: NMUS)
Nemus Bioscience, Inc. (OTCQB: NMUS) is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets, according to the company&#...
Source: StockNewsNow
Date: July, 16 2018 00:49
5 of Today's Biggest Marijuana Stock Losers - Friday, June 15th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Friday, June 15th including mCig, Inc. (OTC:MCIG) and more... Freedom Leaf Inc. (OTC:FRLF) Shares of Freedom Leaf Inc. dropped 13.11% today on higher than average trading volume on the...
Source: Daily Marijuana Observer
Date: June, 15 2018 16:29
5 of Today's Biggest Marijuana Stock Losers - Wednesday, June 13th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Wednesday, June 13th including Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) and more... Grow Condos, Inc. (OTC:GRWC) Shares of Grow Condos, Inc. dropped 4.33% today on lower than ...
Source: Daily Marijuana Observer
Date: June, 13 2018 18:08
Nemus Bioscience to Participate at the 8th Annual LD Micro Invitational
LONG BEACH, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, CEO and Chief Medic...
Source: GlobeNewswire
Date: May, 30 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.330.33360.36670.31226,785
2018-12-120.3110.339250.35990.311130,775
2018-12-110.320.321380.33910.3002295,271
2018-12-100.320.33960.3680.30599,151
2018-12-070.35450.366040.41890.3201310,133

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1391,521226,78540.3558Short
2018-12-1243,643130,77533.3726Cover
2018-12-11134,097295,27145.4149Short
2018-12-10230,550599,15138.4794Short
2018-12-07134,990310,13343.5265Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NMUS.


About Nemus Bioscience, Inc. (OTC: NMUS)

Logo for Nemus Bioscience, Inc. (OTC: NMUS)

Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through our partnership with the University of Mississippi.

 

Contact Information

 

 

Current Management

  • Brian S. Murphy / CEO, Chief Med. Officer
  • Elizabeth Berecz / CFO
  • Punit Dhillon / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member
    • Formerly the VP of finance and operations at Inovio Pharmaceuticals, Inc., Mr. Dhillon raised over million through multiple financings and several licensing deals. He was also instrumental to the successful inlicensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and the merger with VGX Pharmaceuticals. Mr. Dhillon has also been a consultant and board member for several early stage life science companies.
  • Jim Heppell / Independent Director, Audit Committee Member, Compensation Committee Member
  • Brian S. Murphy /

Current Share Structure

  • Market Cap: $20,644,770 - 03/15/2018
  • Authorized: 236,000,000 - 03/15/2018
  • Issue and Outstanding: 100,079,079 - 03/15/2018
  • Float: 14,218,313 - 01/26/2018

 


Recent Filings from (OTC: NMUS)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 17 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 16 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: April, 13 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: March, 23 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 19 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 05 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 05 2018
Amendment to a previously filed Form D
Filing Type: D/AFiling Source: edgar
Filing Date: February, 23 2018

 

 


Daily Technical Chart for (OTC: NMUS)

Daily Technical Chart for (OTC: NMUS)


Stay tuned for daily updates and more on (OTC: NMUS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: NMUS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NMUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NMUS and does not buy, sell, or trade any shares of NMUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/